Introduction
Benign prostate hyperplasia (BPH) is a focal enlargement of the peri-urethral region of the prostate seen in most aging men, which results in symptoms requiring clinical intervention in approximately one-third of men over the age of 60 years. BPH is now the fourth most prevalent disease in men aged more than 50 years 1 .
Though a highly prevalent disorder, the pathogenesis of BPH is not yet well understood. In the past decade an increasing number of reports have suggested a possible relationship between BPH and several metabolic disturbances, known as metabolic syndrome 2, 3 .
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T Afroz 1 , N Sultana 2 , MH Rahman 2 , A Begum 1 , FZ Muna 1 , MM Rahman 3 waist to hip ratio and body mass index (BMI). Similar to obesity the relationship between BPH and dyslipidemia has been documented in several studies. Men with BPH had significantly higher total cholesterol, low-density lipoprotein cholesterol (LDL-C) level and lower the level of HDL-C compared to those in men without BPH 11 . This observation suggests that dyslipidemia per se is not sufficient enough to concur with BPH determinism, but the presence of other metabolic derangements, like T2DM, favor the process, because of an unfavorable total and LDL cholesterol particle size and density 12 .
Hyperglycemia may play a role by increasing cytosolic-free calcium in smooth muscle cells and neural tissue, leading to sympathetic nervous system activation. The IGF pathway may also contribute to the association between insulin resistance and BPH. Insulin shows a structural similarity to IGF-1 and combines with its receptor, which may activate a complex pathway influencing prostate cell growth and proliferation. Alternatively, as insulin level increases, IGF-1 binding protein-1 decreases, thus increasing IGF bioavailability 13 .
The present study was designed in a small group of Bangladeshi population to observe the association of anthropometric and biometrical parameters of metabolic syndrome in patients with benign prostate hyperplasia. However, to our knowledge no such study has yet been done in Bangladesh, though several studies have been done in abroad to establish the association between metabolic syndrome and benign prostate hyperplasia. So this study was designed to see the association of metabolic syndrome with benign prostate hyperplasia which might play some role to reduce the cardiovascular risk in BPH patient by appropriate intervention.
Materials and Method
This observational cross-sectional study was carried out in the Department of Biochemistry, Dhaka Medical College, Dhaka during the period from July 2014 to June 2015. A total of 100 male subjects selected for the study were intolerance and a pro-inflammatory and prothrombotic state that predispose a patient to the risk of developing cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), renal failure and stroke 6 . Worldwide, the prevalence of MetS ranges from 10% to 50%. The MetS as a driver of current epidemics of diabetes and cardiovascular diseases which have become a major challenge to public health around the world 7 The association between Metabolic Syndrome and BPH has also been studied recently. Noninsulin dependent diabetes mellitus (NIDDM), hypertension, obesity and low level of high density lipoprotein cholesterol (HDL-C) levels constitute risk factors for the development of BPH. Men with fast growing BPH had a higher prevalence of NIDDM, hypertension, elevated fasting insulin level and lower HDL-C level than men with slow growing BPH 10 .
Several anthropometric measurements have been used to define obesity including waist circumference, were present, the subject was diagnosed as having metabolic syndrome. Qualitative data were expressed as frequency distribution and percentage and quantitative data were expressed as mean±SD. Data were analysed using windows based computer software device with Statistical Package for Social Science (SPSS) version 20.0. Comparison between groups was done by chi square (x 2 ) test and unpaired student's 't' test as appropriate. The p value <0.05 was taken as level significance. 27.5±3.9 kg/m 2 ) were almost same in both Groups and the differences were not statistically significant (p>0.05). Systolic BP was slightly higher in group I (125±15 mmHg) than that of Group II (122±7 mmHg) and diastolic BP was also slightly higher in group I (84±9 mmHg), than that of Group II (82±5.0 mmHg) but differences were not statistically significant (p>0.05).
Results

As shown in
Table I:
Comparison of various components of metabolic syndrome (Anthropometric measurements) in group I and group II divided into two Groups. Group I consisted of 50 subjects having BPH and Group II consisted of age-matched 50 apparently healthy subjects. Along with anthropometric measurements (WC, BMI, and WHR) BP, fasting blood glucose and lipid profile were assessed and compared between Groups to observe the association between MetS and BPH. A preformed data collection sheet was used to record the data.
After 10-12 hours of overnight fasting, 5 ml of venous blood was collected from median cubital vein of each study participants by disposable syringe with all aseptic precautions. The needle was detached from the nozzle and 3 ml of blood was transferred immediately into a dry and clean plain test tube and rest 2 ml of blood was collected in a Na-Fluoride containing tube. Separated serum and plasma were preserved in eppendorff tube for biochemical assay. All the biochemical tests were performed in the Department of Biochemistry, Dhaka Medical College, Dhaka.
Laboratory Method
l Estimation of fasting plasma glucose was done by 'Glucose Oxidase' (GOD-PAP) method.
l Estimation of fasting serum total cholesterol was done by enzymatic end-point (CHOD-PAP) method.
l Estimation of fasting serum triglycerides (TG) was done by enzymatic (GPO-PAP) method. (2005) criteria among group I and group II. There were significant differences in all of the components of metabolic syndrome between group I and group II. Hypertension was present in 72% (n = 36) and 44% (n = 22) of subjects in group I and group II respectively. FPG was high in group I, 24% (n = 12) and in group II it was 12% (n = 6). WC was low in group I 26% (n = 13) and in group II it was 62% (n = 31). HDL-C was low in group I, 80% (n = 40) and in group II, 40% (n = 20). TG was high in group I, 90% (n = 45) and in group II, 54% (n = 27). All these results were statistically significant except FPG (p value in BP= 0.005; in FPG= 0.118; in WC= 0.001; in HDL-C= 0.001 and in TG= 0.001). 11 . This study showed that reduced HDL-C and increased TG level were noted to be the main determinants of MetS related prostate enlargement 19 .
Our study showed significant differences of assessment of association of MetS with BPH.
To establish the purpose of this cross-sectional study, 50 BPH patients and 50 apparently healthy individuals were taken as group I and group II respectively. The serum lipid profile, fasting plasma glucose and several anthropometric measurements were assessed and statistically compared between groups to observe the association between metabolic syndrome and benign prostate hyperplasia.
Benign prostate hyperplasia (BPH) was seen among elderly people. In this study, age was matched in both groups and age range was 40-70 years. Mean (±SD) age was 59.8±5. 1 years in group I and 58.7±5.7 years in Group II and the difference was not statistically significant (p>0.05). Isa MM et al. also found the similar results in their findings 1 . In the study conducted by Jeon et al 16 it was shown that prevalence of BPH increases with increase in age which is similar to our study.
In our study different anthropometric measurements of components of MetS were taken to observe the association between MetS and BPH. WC was significantly higher in Group II (93.5 ± 11.0 cm) than that in Group I (85.9 ± 9.4 cm) and p-value was 0.001. So, WC was significantly increased in healthy individuals of our study. This may be due to sampling bias where maximum admitted patients in Group I came to DMCH from low socioeconomic Group, mostly living in rural areas and generally have ill health. But the participants of Group II were taken by personal contact from Dhaka city, which were mixed urban and rural population of mixed socioeconomic condition and with average health status. A study reported that waist circumference>90 cm is an important risk factor for prostate hyperplasia 17 which was not consistent with our study.
Waist-hip ratio (Group I: 0.85±0.06 and Group II: 0.86±0.05) was almost same in both the groups in our study and the difference was not statistically significant (p>0.05). The study observed the small but statistically insignificant Bangladesh J Med Biochem 2015; 8 (2) The prevalence of metabolic syndrome in benign prostate hyperplasia was 72% (36 out of 50 patients) and in healthy adults it was 38% (19 out of 50 persons) with OR: 4.19 (1.81-9.72) at 95% CI. Total prevalence of metabolic syndrome in both BPH patients and healthy adults was 55% (55 out of 100 study subjects). This finding supported that there seems to be an association between metabolic syndrome and benign prostate hyperplasia.
It may be concluded that Metabolic syndrome or its components are more common in benign prostate hyperplasia patients. Routine investigations to detect MetS in BPH patients may help to reduce the risk of cerebrovascular diseases, cardiovascular diseases and type 2 diabetes mellitus with appropriate and timely intervention.
